The Role of Cobamamide Supplements in Malnourished Patients
NCT ID: NCT05944744
Last Updated: 2023-07-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
124 participants
INTERVENTIONAL
2023-07-31
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants
NCT06889740
Memantine for Enhanced Stroke Recovery
NCT02144584
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy
NCT05590468
Open-label Clinical Trial of Lacosamide in ALS
NCT03186040
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia
NCT03962114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
The patient is given Cobamamide 2 x 3000 mg for 28 days.
Adenosylcobalamin
The drug contains Cobamamide / Adenosylcobalamin with dose of 3000 mg.
Control
The patient is given placebo 2 x 1 capsule for 28 days.
Placebo
The drug doesn't contain any properties or substances for treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adenosylcobalamin
The drug contains Cobamamide / Adenosylcobalamin with dose of 3000 mg.
Placebo
The drug doesn't contain any properties or substances for treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of malnutrition based on 2019 GLIM criteria
* Participant agree to join the trial by signing infomed consent.
Exclusion Criteria
* Patients who unable to tolerate oral intake and in total parenteral nutrition
* Bowel disorder that caused severe malabsorbtion
* Patients who refuse to join the trial
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Interbat Pharmaceuticals
UNKNOWN
Fakultas Kedokteran Universitas Indonesia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marcellus Simadibrata, Prof. PhD., SpPD, KGEH
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-10-1267
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.